Clinicians and clinical societiesPractising specialists and relationships with major medical societies across Europe and Greater China, built through research, public programmes, evidence translation and invited speaking — including an AI talk at SIMC 2026 in Singapore in engagement with the International Menopause Society.
Researchers and universitiesAcademic collaborators in women's health, linguistics and evidence synthesis — the source of the claims a product will eventually have to defend.
Founders and health-tech teamsEarly-stage companies advised on market pathway, evidence expectations and adoption design rather than on fundraising narrative — including an advisory role with a health-longevity hackathon series run across the Oxford, Cambridge and Imperial network.
Platforms and publishersWorking relationships across the major Chinese audio, social and publishing platforms — Xiaohongshu, Xiaoyuzhou, Ximalaya and Tencent among them — and with national publishers. Distribution into China is a standing capability, not something assembled per project.
Institutions and cultural partnersEmbassies, cultural institutes and public programmes — the route to audiences that clinical channels do not reach.
Communities and audiencesChinese-language health communities convened over several years, giving direct visibility of how guidance is actually received.
Operators and health systemsProcurement, operations and investment counterparts carried over from a decade of multi-market healthcare operating roles.